Acrobiosystems Co.,Ltd. (SHE:301080)
141.07
+18.07 (14.69%)
At close: Sep 30, 2026
Acrobiosystems Revenue
Acrobiosystems had revenue of 264.01M CNY in the quarter ending June 30, 2026, with 31.43% growth. This brings the company's revenue in the last twelve months to 950.35M, up 29.65% year-over-year. In the year 2025, Acrobiosystems had annual revenue of 838.12M with 29.94% growth.
Revenue (ttm)
950.35M
Revenue Growth
+29.65%
P/S Ratio
24.82
Revenue / Employee
1.03M
Employees
926
Market Cap
23.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 838.12M | 193.10M | 29.94% |
| Dec 31, 2024 | 645.02M | 101.37M | 18.65% |
| Dec 31, 2023 | 543.65M | 69.22M | 14.59% |
| Jan 1, 2023 | 474.43M | 89.44M | 23.23% |
| Jan 1, 2022 | 384.99M | 138.67M | 56.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chongqing Zhifei Biological Products | 8.05B |
| Beijing Tiantan Biological Products | 5.65B |
| Yili Chuanning Biotechnology | 4.37B |
| Hualan Biological Engineering | 4.36B |
| Xiamen Amoytop Biotech | 4.02B |
| Suzhou Zelgen Biopharmaceuticals | 1.64B |
| Sinocelltech Group | 1.25B |
| Evopoint Biosciences | 1.11B |